McKesson and CD&R agree to acquire Option Care Health for $5.8 billion

McKesson and Clayton Dubilier & Rice agreed to acquire Option Care Health for approximately $5.8 billion, offering $32.05 per share. The price represents a 37% premium to Option Care Health's Monday closing price.

Analysis

The strategic value is less about adding another distribution channel than controlling more of the care-delivery pathway: if McKesson can connect its existing customer relationships and logistics to Option Care’s infusion network, it may deepen retention and gain insight into where specialty therapies are administered. That is conditional upside, not yet evidence of incremental earnings; integration, customer consent, and any limits on using commercial data will matter. Conversely, independent infusion providers and hospital outpatient sites could face stronger competition if the combined group can offer manufacturers and payers a more coordinated service. The potential vertical link between a major drug distributor and an infusion provider also raises review and contracting questions; watch for regulatory scrutiny or customer concerns about neutrality.

Near term, Option Care’s return is principally a deal-completion and time-value trade, not an operating-growth thesis. The $32.05 offer is a hard reference point, but the article does not establish consideration form, financing, closing conditions, or regulatory timetable. Verify those terms and the live market price before sizing any arbitrage. For McKesson, the strategic rationale is plausible, while shareholder impact depends on its ownership share, funding mix, and whether returns clear the acquisition cost—none is specified. Over 6–18 months, execution and retention of manufacturer, payer, and provider relationships are the key tests. The bullish case weakens if approvals impose material restrictions, key contracts are lost, or McKesson indicates the deal will dilute returns without a credible path to synergies.

Key Decisions for Investors

• Treat OPCH as a conditional merger-arbitrage setup, not an outright growth buy: compare its live price with $32.05 and calculate annualized return against the expected closing timeline only after confirming consideration, financing, termination rights, and regulatory conditions.
• Keep MCK neutral pending deal economics. Reassess when ownership allocation, funding, expected returns, and integration plans are disclosed; a material increase in leverage or evidence of near-term earnings dilution would argue against paying for the strategic narrative.
• Track regulatory filings and customer or contract disclosures for signs that vertical integration could constrain commercial neutrality. A restrictive remedy or loss of important manufacturer, payer, or provider relationships would challenge the synergy thesis and raise completion risk for OPCH.
• Avoid a competitor short on this announcement alone. Revisit the relative trade only if evidence shows infusion volume or contracts shifting from independent providers or hospital outpatient settings to the combined platform.